Neurocrine Biosciences
NBIX
585 hedge funds and large institutions have $12.4B invested in Neurocrine Biosciences in 2025 Q2 according to their latest regulatory filings, with 77 funds opening new positions, 224 increasing their positions, 221 reducing their positions, and 70 closing their positions.
45% more funds holding in top 10
Funds holding in top 10: 11 → 16 (+5)
40% more call options, than puts
Call options by funds: $37.7M | Put options by funds: $27M
16% more capital invested
Capital invested by funds: $10.7B → $12.4B (+$1.75B)
10% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 70
3.08% more ownership
Funds ownership: 96.86% → 99.95% (+3.1%)
1% more repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 221
0% less funds holding
Funds holding: 586 → 585 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$182M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$177M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$133M |
| 4 |
RI
RTW Investments
New York
|
+$122M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$198M |
| 2 |
O
OrbiMed
New York
|
-$56.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$45.2M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$44.2M |
| 5 |
VRS
Virginia Retirement Systems
Richmond,
Virginia
|
-$38.4M |
NBIX Hedge Fund Activity: Q2 2025 in Review
585 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2025, worth a combined $12.4B — up 16% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new NBIX positions and 70 closed out — a net gain of 7 holders — while 224 added to existing stakes and 221 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $182M. The largest seller was BlackRock, cutting an estimated $198M.
- 585 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2025, down from 586 in Q1 2025.
- Funds reported $12.4B of Neurocrine Biosciences stock for Q2 2025, up 16% quarter-over-quarter.
- 77 funds opened new Neurocrine Biosciences positions in Q2 2025 and 70 closed out, a net change of +7 holders.
- The largest Neurocrine Biosciences buyer in Q2 2025 was JP Morgan Chase, an estimated $182M added.
- The largest Neurocrine Biosciences seller in Q2 2025 was BlackRock, an estimated $198M sold.
Based on aggregated 13F filings for Q2 2025.